1
|
Putralis R, Korotkaja K, Kaukulis M, Rudevica Z, Jansons J, Nilova O, Rucins M, Krasnova L, Domracheva I, Plotniece M, Pajuste K, Sobolev A, Rumnieks F, Bekere L, Zajakina A, Plotniece A, Duburs G. Styrylpyridinium Derivatives for Fluorescent Cell Imaging. Pharmaceuticals (Basel) 2023; 16:1245. [PMID: 37765053 PMCID: PMC10535741 DOI: 10.3390/ph16091245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 08/25/2023] [Accepted: 08/29/2023] [Indexed: 09/29/2023] Open
Abstract
A set of styrylpyridinium (SP) compounds was synthesised in order to study their spectroscopic and cell labelling properties. The compounds comprised different electron donating parts (julolidine, p-dimethylaminophenyl, p-methoxyphenyl, 3,4,5-trimethoxyphenyl), conjugated linkers (vinyl, divinyl), and an electron-withdrawing N-alkylpyridinium part. Geminal or bis-compounds incorporating two styrylpyridinium (bis-SP) moieties at the 1,3-trimethylene unit were synthesised. Compounds comprising a divinyl linker and powerful electron-donating julolidine donor parts possessed intensive fluorescence in the near-infrared region (maximum at ~760 nm). The compounds had rather high cytotoxicity towards the cancerous cell lines HT-1080 and MH-22A; at the same time, basal cytotoxicity towards the NIH3T3 fibroblast cell line ranged from toxic to harmful. SP compound 6e had IC50 values of 1.0 ± 0.03 µg/mL to the cell line HT-1080 and 0.4 µg/mL to MH-22A; however, the basal toxicity LD50 was 477 mg/kg (harmful). The compounds showed large Stokes' shifts, including 195 nm for 6a,b, 240 nm for 6e, and 325 and 352 nm for 6d and 6c, respectively. The highest photoluminescence quantum yield (PLQY) values were observed for 6a,b, which were 15.1 and 12.2%, respectively. The PLQY values for the SP derivatives 6d,e (those with a julolidinyl moiety) were 0.5 and 0.7%, respectively. Cell staining with compound 6e revealed a strong fluorescent signal localised in the cell cytoplasm, whereas the cell nuclei were not stained. SP compound 6e possessed self-assembling properties and formed liposomes with an average diameter of 118 nm. The obtained novel data on near-infrared fluorescent probes could be useful for the development of biocompatible dyes for biomedical applications.
Collapse
Affiliation(s)
- Reinis Putralis
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Riga Stradiņš University, LV-1007 Riga, Latvia;
| | - Ksenija Korotkaja
- Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia; (K.K.); (Z.R.); (J.J.); (O.N.); (F.R.); (A.Z.)
| | - Martins Kaukulis
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
- Faculty of Materials Science and Applied Chemistry, Riga Technical University, LV-1048 Riga, Latvia
| | - Zhanna Rudevica
- Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia; (K.K.); (Z.R.); (J.J.); (O.N.); (F.R.); (A.Z.)
| | - Juris Jansons
- Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia; (K.K.); (Z.R.); (J.J.); (O.N.); (F.R.); (A.Z.)
| | - Olga Nilova
- Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia; (K.K.); (Z.R.); (J.J.); (O.N.); (F.R.); (A.Z.)
| | - Martins Rucins
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| | - Laura Krasnova
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| | - Ilona Domracheva
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| | - Mara Plotniece
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Riga Stradiņš University, LV-1007 Riga, Latvia;
- Faculty of Materials Science and Applied Chemistry, Riga Technical University, LV-1048 Riga, Latvia
| | - Karlis Pajuste
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| | - Arkadij Sobolev
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| | - Felikss Rumnieks
- Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia; (K.K.); (Z.R.); (J.J.); (O.N.); (F.R.); (A.Z.)
| | - Laura Bekere
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| | - Anna Zajakina
- Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia; (K.K.); (Z.R.); (J.J.); (O.N.); (F.R.); (A.Z.)
| | - Aiva Plotniece
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Riga Stradiņš University, LV-1007 Riga, Latvia;
| | - Gunars Duburs
- Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia; (R.P.); (M.K.); (M.R.); (L.K.); (I.D.); (K.P.); (A.S.); (L.B.)
| |
Collapse
|
2
|
Legh-Land V, Haddrell AE, Lewis D, Murnane D, Reid JP. Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System. Pharmaceutics 2021; 13:pharmaceutics13070941. [PMID: 34202458 PMCID: PMC8309010 DOI: 10.3390/pharmaceutics13070941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 06/05/2021] [Accepted: 06/06/2021] [Indexed: 11/29/2022] Open
Abstract
As pulmonary drug deposition is a function of aerosol particle size distribution, it is critical that the dynamics of particle formation and maturation in pMDI sprays in the interim between generation and inhalation are fully understood. This paper presents an approach to measure the evaporative and condensational fluxes of volatile components and water from and to solution pMDI droplets following generation using a novel technique referred to as the Single Particle Electrodynamic Lung (SPEL). In doing so, evaporating aerosol droplets are shown capable of acting as condensation nuclei for water. Indeed, we show that the rapid vaporisation of volatile components from a volatile droplet is directly correlated to the volume of water taken up by condensation. Furthermore, a significant volume of water is shown to condense on droplets of a model pMDI formulation (hydrofluoroalkane (HFA), ethanol and glycerol) during evaporative droplet ageing, displaying a dramatic shift from a core composition of a volatile species to that of predominantly water (non-volatile glycerol remained in this case). This yields a droplet with a water activity of 0.98 at the instance of inhalation. The implications of these results on regional and total pulmonary drug deposition are explored using the International Commission of Radiological Protection (ICRP) deposition model, with an integrated semi-analytical treatment of hygroscopic growth. Through this, droplets with water activity of 0.98 upon inhalation are shown to produce markedly different dose deposition profiles to those with lower water activities at the point of inspiration.
Collapse
Affiliation(s)
- Victoria Legh-Land
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK; (V.L.-L.); (D.M.)
| | | | - David Lewis
- Chiesi Farmaceutici S.p.A, Chippenham SN14 0AB, UK;
| | - Darragh Murnane
- School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK; (V.L.-L.); (D.M.)
| | - Jonathan P. Reid
- School of Chemistry, University of Bristol, Bristol BS8 1TS, UK;
- Correspondence: ; Tel.: +44-117-331-7388
| |
Collapse
|
3
|
Abstract
Aerosols are dynamic systems, responding to variations in the surrounding environmental conditions by changing in size, composition and phase. Although, widely used in inhalation therapies, details of the processes occurring on aerosol generation and during inhalation have received little attention. Instead, research has focused on improvements to the formulation of the drug prior to aerosolization and the resulting clinical efficacy of the treatment. Here, we highlight the processes that occur during aerosol generation and inhalation, affecting aerosol disposition when deposited and, potentially, impacting total and regional doses. In particular, we examine the response of aerosol particles to the humid environment of the respiratory tract, considering both the capacity of particles to grow by absorbing moisture and the timescale for condensation to occur. [Formula: see text].
Collapse
|
4
|
Devillier P, Garrigue E, D'Auzers G, Monjotin N, Similowski T, Clerc T. V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results. Respir Res 2015; 16:68. [PMID: 26050967 PMCID: PMC4462001 DOI: 10.1186/s12931-015-0227-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 05/29/2015] [Indexed: 01/08/2023] Open
Abstract
Background Long acting bronchodilators are the standard of care in the management of chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the efficacy and safety of V0162, a novel anticholinergic agent with bronchodilator properties, in preclinical models and in patients with COPD. Methods Guinea pigs were used to evaluate the impact of V0162 on the acetylcholine or histamine-induced bronchoconstriction. V0162 was also investigated in an allergic asthma model on ovalbumin-sensitized guinea pig. For clinical investigations, healthy volunteers were included in a dose-escalation, randomized, placebo-controlled phase I study to determine the maximal tolerated dose, followed by a randomized, placebo-controlled, cross-over phase II study in patients with COPD. V0162 was given via inhalation route. The objectives of the phase I/II study were to assess the safety and efficacy of V0162, in terms of bronchodilation and reduction in hyperinflation. Results Preclinical results showed that V0162 was able to prevent bronchoconstriction induced either by acetylcholine or histamine. V0162 reversed the bronchoconstriction and airway inflammation caused by ovalbumin challenge in sensitized guinea pigs. In the healthy volunteers study, 88 subjects were enrolled: 66 received V0162 and 22 received placebo. No particular safety concerns were raised. The maximal tolerated dose was not reached and the dose escalation was stopped at 2400 μg. A total of 20 patients with COPD were then enrolled. All patients received a single-dose of V0162 1600 μg and of placebo in two alternating periods. In COPD patients, V0162 demonstrated a significant increase in FEV1 compared with placebo (148 ± 137 ml vs. 36 ± 151 ml, p = 0.003). This bronchodilatory effect was corroborated by a reduction in hyperinflation. There was a trend toward dyspnea relief (change in visual analog scale at 22 h, −15.1 ± 26.0 mm vs.- 5.3 ± 28.8 mm with placebo, p = 0.054). No serious adverse events (AEs) were reported. Most common AEs were productive and non-productive cough, dyspnea and pruritus. Conclusions V0162 improved pulmonary function and tended to improve dyspnea in patients with COPD over more than 24 h. The slight plasmatic exposure observed might support the good safety profile. Trial registration ClinicalTrials.gov identifier: NCT01348555
Collapse
Affiliation(s)
- Philippe Devillier
- UPRES EA 220, Hôpital Foch, Université de Versailles Saint Quentin, 11 rue Guillaume Lenoir, Suresnes, 92150, France.
| | - Eric Garrigue
- Centre de Recherche et de Développement Pierre Fabre Toulouse, 3 Avenue Hubert Curien BP 13562, 31035, Toulouse, France.
| | - Guillaume D'Auzers
- Centre de Recherche et de Développement Pierre Fabre Toulouse, 3 Avenue Hubert Curien BP 13562, 31035, Toulouse, France.
| | - Nicolas Monjotin
- Institut de Recherche Pierre Fabre, Service de Pharmacologie, CEPC Bel Air de Campans, Castres Cedex, 81106, France.
| | - Thomas Similowski
- AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale (Département "R3S"), 47-83 Bd de l'Hôpital, F-75013, Paris, France. .,Sorbonne Universités, UPMC Paris 06, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", F-75005, Paris, France. .,INSERM, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", F-75005, Paris, France.
| | - Thierry Clerc
- Centre de Recherche et de Développement Pierre Fabre Toulouse, 3 Avenue Hubert Curien BP 13562, 31035, Toulouse, France.
| |
Collapse
|
5
|
Mortensen NP, Durham P, Hickey AJ. The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. J Microencapsul 2014; 31:785-95. [DOI: 10.3109/02652048.2014.932029] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
6
|
Assessing and accessing the small airways; implications for asthma management. Pulm Pharmacol Ther 2012; 26:172-9. [PMID: 23073337 DOI: 10.1016/j.pupt.2012.10.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2012] [Revised: 10/01/2012] [Accepted: 10/06/2012] [Indexed: 11/21/2022]
Abstract
Despite the wealth of experience in the management of asthma, the disease remains inadequately controlled in some patients, who face long-term respiratory impairment and disability. The disease has been characterised as an inflammatory condition affecting first the larger airways and eventually the smaller airways, but there is evidence that peripheral airway involvement defines a particular and more severe phenotype of asthma. For this reason, assessing functional and biological parameters reflective of small airways involvement is important prognostically. No assessment method is universally and directly representative of peripheral airway function, but the traditional spirometric tests, including vital capacity, residual volume and forced vital capacity, are somewhat correlated with this function; useful methods for further assessment include the single-breath nitrogen wash-out test, impulse oscillometry, nitrous oxide and exhaled breath concentrate measurements, as well as computed tomography to reflect air trapping and response to treatment. Formulation advancements have made for easier treatment access to the smaller airways, with the new extrafine formulations resulting in better asthma control compared with non-extrafine formulations.
Collapse
|
7
|
van den Berge M, ten Hacken NHT, Postma DS. Small airway disease in asthma: a need for awareness in patients and doctors. CLINICAL RESPIRATORY JOURNAL 2011; 5:123-4. [PMID: 21679347 DOI: 10.1111/j.1752-699x.2011.00249.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Bjermer L. Targeting small airways, a step further in asthma management. CLINICAL RESPIRATORY JOURNAL 2011; 5:131-5. [PMID: 21501394 DOI: 10.1111/j.1752-699x.2011.00240.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION During the last decade, small airway (SA) involvement in asthma and Chronic Obstructive Pulmonary Disease (COPD) have reached increasing attention. Originally referred to as the 'silent zone', SA may not be that silent after all. Important clinical correlates are asthma exacerbations and airways remodelling, exercise asthma and nocturnal asthma. Thus, to control pathology in the SA has become a desirable goal in asthma management. OBJECTIVES The scope of this review is to give a brief overview of the current status on SA in asthma, how to monitor and to diagnose SA inflammation and finally highlight some important treatment strategies. RESULTS/CONCLUSION New tools have been developed to monitor SA function; these implies the use of imaging techniques and respiratory physiology, targeting SA function. Fractional exhaled nitric oxide and the combined use of hyperresponsiveness testing with impulsoscillometry is another option. The introduction of ultrafine aerosols has provided new tools for to treat SA inflammation. The challenge for the future will be to define the optimal particle size and device for maximal deposition in entire lung, including the small airways. Moreover, we also need strategies for increasing the therapeutic ratio, i.e. increasing lung deposition without increasing systemic side effects. Another challenge is to design and to perform clinical trials, targeting effects in SA, proving the clinical importance of SA treatment in a large number of patients. The latter also imply education of our medical authorities, communicating that asthma is more than a beta-2 agonist responsive central airway disorder of the lungs.
Collapse
Affiliation(s)
- Leif Bjermer
- Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden.
| |
Collapse
|